Portola Pharmaceuticals (PTLA) Pummeled After Betrixaban Fails Phase 3 APEX Study

Shares of Portola Pharmaceuticals were off -7.97 or -27.85 percent to $20.65 per share in this morning's premarket after trading was halted in the stock pending news. The company subsequently released the results from a Phase 3 APEX trial of its drug Betrixaban, which failed to achieve its primary endpoint in the first cohort. Portola ... READ MORE Read the rest of Portola Pharmaceuticals (PTLA) Pummeled After Betrixaban Fails Phase 3 APEX Study at InvestorGuide.com .